最新发布
Novartis drops TREM2 antibody in ALS after Phase 2 miss
Why it matters: ALS drug development has produced far more failures than approvals, and no treatment can currently stop or reverse the disease. For Novartis, the setback also comes amid a difficult stretch for its pipeline: pelacarsen missed its Phase 3 primary endpoint on Sept. 4, and del-desiran, the lead drug from its Avidity Biosciences takeover, failed four days later.
Victoria backs dairy export push across Asia with $250,000 market access programme
Victoria is stepping up its push to expand dairy exports across Asia, with the state government partnering with Dairy Au…
Vietnam gains coffee market share in Japan as imports rise 5% in first half of 2026
Vietnam is gaining ground in Japan’s coffee market, with shipments rising 5% in volume during the first half of 20…
内蒙古3个化工园区拟通过复核，1个拟通过认定
大农化网报道： 近期，内蒙古自治区工业和信息化厅分别公示了第四批拟通过复核化工园区名单和拟认定化工园区名单。 9月10日，内蒙古自治区工信厅发布公示，呼和浩特托克托经济开发区、包头土右新型工业园区、赤峰高新技术产业开发区元宝山产业园等3个化…
中国台湾地区首登！洽益化学氟啶虫胺腈制剂正式落地，加速全球登记布局并寻求原药战略合作
随着抗药性管理成为全球作物保护市场日益重要的课题，氟啶虫胺腈（Sulfoxaflor）凭借其独特的化学结构与作用特性，已成为全球刺吸式害虫防治的重要杀虫剂之一，广泛应用于蓟马、蚜虫、粉虱、飞虱及介壳虫等害虫防治，覆盖多种重要经济作物。 &n…
靶向缓控释技术在水稻纹枯病防治中的时空匹配与效能优化研究
水稻纹枯病是水稻生产中最具毁灭性的病害之一，其病原菌（立枯丝核菌）长期潜伏于荫蔽叶鞘之间，药剂难以抵达；而传统控释制剂又普遍存在"盲目释放"的弊端——药剂释放与病菌侵染在时间和空间上错位，导致防效不稳定、用药量居高不下。…
吡唑醚菌酯获欧盟15年满额续展：用途限制松绑，杂质、助剂合规等同步收紧
大农化网报道：2026年9月8日，欧盟委员会通过实施条例（EU）2026/1976，依据欧洲议会及理事会第1107/2009号条例第20(1)条，正式续展活性物质吡唑醚菌酯（pyraclostrobin）的批准，并同步修订实施条例（EU）第…
润丰设立欧盟登记推进共享中心，以波兰为支点重构欧盟登记与市场协同体系
"欧盟市场" 可能是作物保护行业最容易被一眼带过去的四个字。看起来是一个市场，但过去几年的实际感受是：各国的竞争逻辑在分化，而且分化得比想象中快。 最近，润丰在波兰做了一件想了很久的事：欧盟登记推进共享中心正式挂牌运行。…
农业农村部拟出台互联网经营农药负面清单，十类产品禁止通过线上销售
大农化网报道：9月16日，农业农村部种植业管理司发布关于征求互联网经营农药负面清单意见的函【农农（农药）〔2026〕51号】。 为加强互联网经营农药的监督管理，保障农产品质量安全和人畜安全，保护农林业生产与生态环境，根据《农药管理条例》、《…
Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma
Vivek Adarsh’s reasons for founding Mithrl are quite personal. About 15 years ago, his grandfather passed away from acute kidney disease. And while today there are approved treatments for the disease, 15 years ago there were no FDA-approved drugs specifically for the condition. Adarsh, a trained computer scientist, wanted to address this problem across multiple disease areas that still lack effective treatments today. Three years ago, he co-founded Mithrl, a company whose stated mission is to “help R&D teams go from idea to IND, 50% faster.”